Cost-effectiveness of C-reactive protein point of care testing for safely reducing antibiotic consumption for acute exacerbations of chronic obstructive pulmonary disease as part of the multicentre, parallel-arm, open, individually randomised, controlled PACE trial.

ABSTRACT:

Objectives

Many patients presenting with acute exacerbations of chronic obstructive pulmonary disease (AECOPD) in primary care do not benefit from antibiotics. Excessive use wastes resources, promotes antimicrobial resistance and can harm patients.

Design

We conducted a within-trial economic evaluation, using a UK National Health Service perspective, as part of the multicentre, parallel-arm, open, individually randomised, controlled PACE trial.

Setting

Participating general practices in primary care.

Participants

PACE included 324 and 325 consenting participants presenting with AECOPD in the usual-care and CRP-guided groups, respectively.

Intervention

We assessed the cost-effectiveness (CE) of a C-reactive protein point-of-care-test (CRP-POCT) in additio

SUBMITTER: Sewell B 

PROVIDER: S-EPMC11660330 | biostudies-literature | 2024 Nov

REPOSITORIES: biostudies-literature